Navigation Links
New Drug Promises Hope In Multiple Drug Resistant And Latent TB Treatment

FAS20013, a tuberculosis drug, currently in the experimental phase has offered hope in the treatment of multiple drug resistant and latent infections as well. The mechanism of action of the new drug is different // than those used for conventional treatment.

The drug targets slow growing mycobacteria involved in the disease process and induces selective killing of the same. The other drugs target a broad spectrum of non-pathogenic microorganisms that enables development of drug resistance. Nearly all isolates have been shown to be susceptible to the compound and no resistance has been observed.

The compound is the first ever known to combat latent infection. Following infection, some patients go into a latent phase where no symptoms are seen. Such patients are not capable of infecting others, as they do not have an active infection. However, they can develop active infection at any time. Worldwide, more than 2 billion people have this latent form of the disease.

Furthermore, the drug action is precipitated in just 4 hours while Rifampicin or Isoniazid needs 12 to 14 hours to destroy the pathogen. The pharmaceutical company FASgen, Inc., is working towards marketing the novel drug for commercial use.

Overcoming multiple drug resistance in tuberculosis represents a significant challenge in the successful treatment of tuberculosis. It is associated with a fatality rate ranging from 20 to 80%. The presence of an uncontrollable active infection and failure to respond to any therapy are strong indications for isolation of the patient to prevent the emergence of drug resistant strains in the population. In worst cases, it may be even required to perform surgical resection of a part of the lung. The cost associated with such a treatment can be as high as $250,000.

The drug is currently being investigated in laboratory animals to estimate the beneficial and toxic effects. An application would soon be submitted to th e Food and Drug Administration (FDA) regarding proceeding with clinical trials of the investigational new drug (IND). If promising results are obtained, we could soon have an anti-tuberculous drug for treatment of MDR-TB.


'"/>




Related medicine news :

1. Marijuana-Derived Drug Promises Hope In Treating Bladder Infection
2. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
3. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
4. Maternal Vitamin D Supplementation Promises Healthy Bones In Child
5. Raw Vegan Diet Promises Lightweight, Healthy Bones
6. Stem Cell Transplantation Promises Cure for Type 2 Diabetes
7. Health Minister Promises Strict Quality Control On Herbal Medicines
8. Anti-Cancer Treatment Promises Hope in Bird Flu Treatment
9. Nanotechnology Promises Huge Medical Benefits
10. Health Minister Promises New Benchmark for Wait Times
11. Terahertz Imaging Promises To Revolutionize Breast Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... Indianapolis, Ind. (PRWEB) , ... May 03, 2016 ... ... today that it has been selected by Tidelands Health, a three hospital system ... need to be constantly on the lookout for technology that enhances communication, drives ...
(Date:5/3/2016)... ... , ... Nationally recognized personal injury law firm Monge & Associates is honoring Moms ... who wants one for their Mother or any other mother figure. , According to law ... Monge goes on to say, “we are choosing to do this by giving free ...
(Date:5/3/2016)... ... 2016 , ... Ogawa World USA introduced the first of its kind ... Smart Application. The Smart 3D combines the best in technological advancement, design, and massage ... and specialized massage program, each user has a tailored experience unparalleled by any other ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... Canada’s top Information and Communication Technology (ICT) companies in the annual Branham300 listing. ... companies operating in Canada, as ranked by revenue. , “We are honored ...
(Date:5/3/2016)... ... May 03, 2016 , ... Huntington Beach orthopedic ... of surgical procedure that can be used to diagnose and treat joint problems. During ... inserted. These instruments include a special lighting system and lens that illuminate and magnify ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... 2, 2016 Kalorama Information noted the 5 ... market in a recent white paper.  The healthcare market ... usage, a growing market are among the top drivers ... report EMR 2016: The Market for Electronic ... complete study of the EMR industry, and the report ...
(Date:5/2/2016)...  Deerfield announced today it led the $44.5 ... Graybug Vision is an early stage pharmaceutical company ... for ocular diseases including wet age-related macular degeneration ... developed at Johns Hopkins University and has been ... Graybug Vision is developing ophthalmology products enabling ...
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
Breaking Medicine Technology: